Drugs / Omega-3 supplement
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04053218 | Jan 2018 → Sep 2020 | cognitive impairment with or without cerebellar ataxia, mood disorder, protein-energy malnutrition | The University of The West Indies | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00135902 Comparator | Feb 2005 → Mar 2007 | — | The George Washington University Biostatistics Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | omega-3 supplement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04053218 ↗ |
| Known as | Omega-3 | “Omega-3, a polyunsaturated fatty acid nutritional supplement” NCT00135902 ↗ |
| Route | Oral | “a daily supplement of Omega-3 capsules” NCT00135902 ↗ |